231 related articles for article (PubMed ID: 29991556)
21. JAK2V617F Megakaryocytes Promote Hematopoietic Stem/Progenitor Cell Expansion in Mice Through Thrombopoietin/MPL Signaling.
Zhang Y; Lin CHS; Kaushansky K; Zhan H
Stem Cells; 2018 Nov; 36(11):1676-1684. PubMed ID: 30005133
[TBL] [Abstract][Full Text] [Related]
22. The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm.
Sangkhae V; Etheridge SL; Kaushansky K; Hitchcock IS
Blood; 2014 Dec; 124(26):3956-63. PubMed ID: 25339357
[TBL] [Abstract][Full Text] [Related]
23. Determining the role of inflammation in the selection of JAK2 mutant cells in myeloproliferative neoplasms.
Zhang J; Fleischman AG; Wodarz D; Komarova NL
J Theor Biol; 2017 Jul; 425():43-52. PubMed ID: 28501635
[TBL] [Abstract][Full Text] [Related]
24. Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells.
Mansier O; Kilani B; Guitart AV; Guy A; Gourdou-Latyszenok V; Marty C; Parrens M; Plo I; Vainchenker W; James C
Blood; 2019 Dec; 134(26):2383-2387. PubMed ID: 31697834
[TBL] [Abstract][Full Text] [Related]
25. Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F.
Lundberg P; Takizawa H; Kubovcakova L; Guo G; Hao-Shen H; Dirnhofer S; Orkin SH; Manz MG; Skoda RC
J Exp Med; 2014 Oct; 211(11):2213-30. PubMed ID: 25288396
[TBL] [Abstract][Full Text] [Related]
26. Focus on the epigenome in the myeloproliferative neoplasms.
Kim E; Abdel-Wahab O
Hematology Am Soc Hematol Educ Program; 2013; 2013():538-44. PubMed ID: 24319229
[TBL] [Abstract][Full Text] [Related]
27. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms.
Arranz L; Sánchez-Aguilera A; Martín-Pérez D; Isern J; Langa X; Tzankov A; Lundberg P; Muntión S; Tzeng YS; Lai DM; Schwaller J; Skoda RC; Méndez-Ferrer S
Nature; 2014 Aug; 512(7512):78-81. PubMed ID: 25043017
[TBL] [Abstract][Full Text] [Related]
28. A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression.
Chapeau EA; Mandon E; Gill J; Romanet V; Ebel N; Powajbo V; Andraos-Rey R; Qian Z; Kininis M; Zumstein-Mecker S; Ito M; Hynes NE; Tiedt R; Hofmann F; Eshkind L; Bockamp E; Kinzel B; Mueller M; Murakami M; Baffert F; Radimerski T
PLoS One; 2019; 14(10):e0221635. PubMed ID: 31600213
[TBL] [Abstract][Full Text] [Related]
29. The JAK2 mutation.
Merchant S
Int Rev Cell Mol Biol; 2021; 365():117-162. PubMed ID: 34756242
[TBL] [Abstract][Full Text] [Related]
30. Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms.
Sharma V; Wright KL; Epling-Burnette PK; Reuther GW
Front Immunol; 2020; 11():604142. PubMed ID: 33329600
[TBL] [Abstract][Full Text] [Related]
31. Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator.
Kameda T; Shide K; Yamaji T; Kamiunten A; Sekine M; Taniguchi Y; Hidaka T; Kubuki Y; Shimoda H; Marutsuka K; Sashida G; Aoyama K; Yoshimitsu M; Harada T; Abe H; Miike T; Iwakiri H; Tahara Y; Sueta M; Yamamoto S; Hasuike S; Nagata K; Iwama A; Kitanaka A; Shimoda K
Blood; 2015 Jan; 125(2):304-15. PubMed ID: 25395421
[TBL] [Abstract][Full Text] [Related]
32. The regulation of normal and neoplastic hematopoiesis is dependent on microenvironmental cells.
Kaushansky K; Zhan H
Adv Biol Regul; 2018 Aug; 69():11-15. PubMed ID: 29970351
[TBL] [Abstract][Full Text] [Related]
33. PBX1-directed stem cell transcriptional program drives tumor progression in myeloproliferative neoplasm.
Muggeo S; Crisafulli L; Uva P; Fontana E; Ubezio M; Morenghi E; Colombo FS; Rigoni R; Peano C; Vezzoni P; Della Porta MG; Villa A; Ficara F
Stem Cell Reports; 2021 Nov; 16(11):2607-2616. PubMed ID: 34678207
[TBL] [Abstract][Full Text] [Related]
34. TET2 loss, a rescue of JAK2V617F HSCs.
Vainchenker W; Plo I
Blood; 2015 Jan; 125(2):212-3. PubMed ID: 25573967
[TBL] [Abstract][Full Text] [Related]
35. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.
Stivala S; Codilupi T; Brkic S; Baerenwaldt A; Ghosh N; Hao-Shen H; Dirnhofer S; Dettmer MS; Simillion C; Kaufmann BA; Chiu S; Keller M; Kleppe M; Hilpert M; Buser AS; Passweg JR; Radimerski T; Skoda RC; Levine RL; Meyer SC
J Clin Invest; 2019 Mar; 129(4):1596-1611. PubMed ID: 30730307
[TBL] [Abstract][Full Text] [Related]
36. The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity.
James C; Mazurier F; Dupont S; Chaligne R; Lamrissi-Garcia I; Tulliez M; Lippert E; Mahon FX; Pasquet JM; Etienne G; Delhommeau F; Giraudier S; Vainchenker W; de Verneuil H
Blood; 2008 Sep; 112(6):2429-38. PubMed ID: 18612101
[TBL] [Abstract][Full Text] [Related]
37. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
Chachoua I; Pecquet C; El-Khoury M; Nivarthi H; Albu RI; Marty C; Gryshkova V; Defour JP; Vertenoeil G; Ngo A; Koay A; Raslova H; Courtoy PJ; Choong ML; Plo I; Vainchenker W; Kralovics R; Constantinescu SN
Blood; 2016 Mar; 127(10):1325-35. PubMed ID: 26668133
[TBL] [Abstract][Full Text] [Related]
38. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.
Winter PS; Sarosiek KA; Lin KH; Meggendorfer M; Schnittger S; Letai A; Wood KC
Sci Signal; 2014 Dec; 7(357):ra122. PubMed ID: 25538080
[TBL] [Abstract][Full Text] [Related]
39. Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations.
Austin RJ; Straube J; Bruedigam C; Pali G; Jacquelin S; Vu T; Green J; Gräsel J; Lansink L; Cooper L; Lee SJ; Chen NT; Lee CW; Haque A; Heidel FH; D'Andrea R; Hill GR; Mullally A; Milsom MD; Bywater M; Lane SW
Leukemia; 2020 Apr; 34(4):1075-1089. PubMed ID: 31732720
[TBL] [Abstract][Full Text] [Related]
40. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
Dunbar A; Nazir A; Levine R
Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
